^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIR3DL2 Q386E

    i
    Other names: KIR3DL2, Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2, CD158K, Killer Cell Immunoglobulin-Like Receptor Three Domains Long Cytoplasmic Tail, Killer Cell Immunoglobulin-Like Receptor 3DL2, P70 Natural Killer Cell Receptor Clone CL-5, Natural Killer-Associated Transcript 4, CD158 Antigen-Like Family Member K, MHC Class I NK Cell Receptor, P70 NK Receptor CL-5, NKAT-4, NKAT4, Killer Cell Immunoglobulin-Like Receptor 2DL2, Killer-Cell Immunoglobulin-Like Rece
    Entrez ID:
    3812
    Related biomarkers:
    Expression
    Mutation
    3years
    Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma (ASH 2021)
    Final data will be presented at the time of the conference. Overall, the results from this Phase 2 study with tipifarnib demonstrated very encouraging efficacy in patients with CXCL12-expressing subtypes of PTCL (AITL and PTCL-CXCL12+) and showed a tolerable safety profile.
    Clinical • P2 data
    |
    ALK (Anaplastic lymphoma kinase) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2)
    |
    ALK negative • CXCL12 expression • KIR3DL2 C336R • KIR3DL2 Q386E
    |
    Zarnestra (tipifarnib)